Amplitude Surgical lists on Euronext Paris

Raises €100 million, market capitalisation €235 million

Paris – 30 June  2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1],today celebrated the listing of Amplitude Surgical, a leading French player on the global surgical technology market for lower-limb orthopedics, on 26 June 2015. Amplitude Surgical is listed on Euronext Paris in Compartiment B.

Founded in 1997 in Valence, France, Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery.The Group also provides innovative services that add significant value to its product range, such as the AMPLIVISION® computer-assisted surgical navigation system, the i.M.A.G.E® single-use made-to-measure instrument system and the E.T.O.I.L.E® technology platform for anterior approaches resulting in less-invasive surgery.

Amplitude Surgical (ticker code: AMPLI) was listed through the admission to trading of the 46,929,852 shares making up its equity on 26 June 2015including 20,000,000new shares issued under a Global Offering[2].

The admission and issue price of ABIVAX shares was set at €5 per share. Market capitalisation was €234,649,260 million on the day of listing, and the transaction raised a total of €100million.

Olivier Jallabert, Chairman and CEO of Amplitude Surgical, said:“I am delighted with our successful listing on Euronext, which has expended the steadily growing compartment dedicated to healthcare. This is a key stage in pursuing our company’s international drive, both for the deploymnet of our commercial strategy and for changes in our capital structure. I would like to extend warm thanks to the shareholders that have joined us on this occasion.”

Eric Forest, CEO of EnterNext, said: “We are delighted to welcome Amplitude Surgical to listing on Euronext. EnterNext works with many medtech companies that turn to financial markets to raise the capital they need to accelerate their growth. Listing will bring Amplitude Surgical the resources it needs to step up deployment of its strategy, in particular on international markets.”

To celebrate listing, Olivier Jallabert rang the bell closing trading on Euronext markets. He was accompanied by Amplitude Surgical’s management, advisers and the EnterNext team.



[1]Small and medium-size companies
[2]
The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries

 

About EuronextEuronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.5 trillion in market capitalisation as of end March 2019, Euronext is an unmatched blue chip franchise that has 24 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities ,FX,  Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs.

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2019, Euronext N.V. - All rights reserved.